# A Study to Test the Long-term Safety, Tolerability and Efficacy of Brivaracetam in Study Participants 2 to 26 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy

> **NCT05109234** · PHASE3 · COMPLETED · sponsor: **UCB Biopharma SRL** · enrollment: 84 (actual)

## Conditions studied

- Childhood Absence Epilepsy
- Juvenile Absence Epilepsy

## Interventions

- **DRUG:** Brivaracetam Film-coated tablet
- **DRUG:** Brivaracetam oral solution

## Key facts

- **NCT ID:** NCT05109234
- **Lead sponsor:** UCB Biopharma SRL
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-03-30
- **Primary completion:** 2025-03-18
- **Final completion:** 2025-03-18
- **Target enrollment:** 84 (ACTUAL)
- **Last updated:** 2025-10-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05109234

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05109234, "A Study to Test the Long-term Safety, Tolerability and Efficacy of Brivaracetam in Study Participants 2 to 26 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT05109234. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*